Continue to site >
Trending ETFs
You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Name

As of 11/01/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Invesco Biotechnology & Genome ETF

PBE | ETF

$69.14

$246 M

0.05%

$0.03

0.58%

Vitals

YTD Return

5.1%

1 yr return

23.1%

3 Yr Avg Return

-3.2%

5 Yr Avg Return

6.0%

Net Assets

$246 M

Holdings in Top 10

60.6%

52 WEEK LOW AND HIGH

$68.2
$53.55
$71.97

Expenses

OPERATING FEES

Expense Ratio 0.58%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 151.00%

Redemption Fee N/A

Min Investment

Standard (Taxable)

N/A

IRA

N/A

Fund Classification

Fund Type

Exchange Traded Fund

Name

As of 11/01/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

Invesco Biotechnology & Genome ETF

PBE | ETF

$69.14

$246 M

0.05%

$0.03

0.58%

PBE - Profile

Distributions

  • YTD Total Return 5.1%
  • 3 Yr Annualized Total Return -3.2%
  • 5 Yr Annualized Total Return 6.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.30%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Quarterly

Fund Details

  • Legal Name
    Invesco Biotechnology & Genome ETF
  • Fund Family Name
    INVESCOETF
  • Inception Date
    Jun 23, 2005
  • Shares Outstanding
    3820000
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Peter Hubbard

Fund Description

The Fund generally will invest at least 90% of its total assets in securities that comprise the Underlying Index.
Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC (“ICE Data” or the “Index Provider”) compiles and maintains the Underlying Index, which is composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, and are companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. These companies may include biopharmaceutical companies that actively participate in the research and development, animal testing and partial human testing phases of drug development, typically using biotechnological techniques that require the use of living organisms, cells and/or components of cells; outsourced services companies that utilize drug delivery technologies in the development of therapeutics for the biopharmaceutical industry or provide biopharmaceutical companies with novel biological targets and drug leads, and scientific products such as bio-analytical instruments, reagents, and chemicals.
As of June 30, 2024, the Underlying Index was comprised of 30 constituents with market capitalizations ranging from $653.6 million to $167.6 billion.
The Fund employs a “full replication” methodology in seeking to track the Underlying Index, meaning that the Fund generally invests in all of the securities comprising the Underlying Index in proportion to their weightings in the Underlying Index.
The Fund is “non-diversified” and therefore is not required to meet certain diversification requirements under the  Investment Company Act of 1940, as amended (the “1940 Act”).
Concentration Policy. The Fund will concentrate its investments (i.e., invest 25% or more of the value of its total assets) in securities of issuers in any one industry or group of industries only to the extent that the Underlying Index reflects a concentration in that industry or group of industries. The Fund will not otherwise concentrate its investments in securities of issuers in any one industry or group of industries. As of April 30, 2024, the Fund had significant exposure to the biotechnology and genome industry. The Fund’s portfolio holdings, and the extent to which it concentrates its investments, are likely to change over time.
Read More

PBE - Performance

Return Ranking - Trailing

Period PBE Return Category Return Low Category Return High Rank in Category (%)
YTD 5.1% -26.9% 24.4% 84.91%
1 Yr 23.1% -7.8% 49.2% 35.22%
3 Yr -3.2%* -32.5% 9.5% 77.63%
5 Yr 6.0%* -4.9% 13.7% 80.82%
10 Yr 3.7%* 0.1% 13.3% 94.59%

* Annualized

Return Ranking - Calendar

Period PBE Return Category Return Low Category Return High Rank in Category (%)
2023 3.7% -12.6% 19.0% 38.36%
2022 -10.8% -53.9% 3.2% 30.26%
2021 1.5% -39.6% 24.2% 42.11%
2020 25.6% -13.6% 178.2% 16.78%
2019 18.7% 3.8% 63.8% 69.92%

Total Return Ranking - Trailing

Period PBE Return Category Return Low Category Return High Rank in Category (%)
YTD 5.1% -26.9% 24.4% 84.91%
1 Yr 23.1% -7.8% 49.2% 35.22%
3 Yr -3.2%* -32.5% 9.5% 77.63%
5 Yr 6.0%* -4.9% 13.7% 80.82%
10 Yr 3.7%* 0.1% 13.3% 94.59%

* Annualized

Total Return Ranking - Calendar

Period PBE Return Category Return Low Category Return High Rank in Category (%)
2023 3.7% -12.6% 19.0% 59.12%
2022 -10.8% -53.9% 3.7% 43.42%
2021 1.5% -33.9% 26.0% 77.63%
2020 25.7% -0.7% 180.6% 38.26%
2019 18.7% 4.6% 63.8% 91.73%

PBE - Holdings

Concentration Analysis

PBE Category Low Category High PBE % Rank
Net Assets 246 M 6.87 M 47.2 B 63.52%
Number of Holdings 33 26 430 94.34%
Net Assets in Top 10 164 M 2.12 M 22.1 B 59.75%
Weighting of Top 10 60.58% 18.4% 79.7% 14.47%

Top 10 Holdings

  1. Invesco Private Prime Fund 14.46%
  2. Invesco Private Government Fund 5.54%
  3. Illumina, Inc. 5.41%
  4. Gilead Sciences, Inc. 5.37%
  5. Incyte Corp. 5.13%
  6. BioMarin Pharmaceutical Inc. 5.11%
  7. Vertex Pharmaceuticals Inc. 5.01%
  8. Regeneron Pharmaceuticals, Inc. 5.00%
  9. Amgen Inc. 5.00%
  10. Neurocrine Biosciences, Inc. 4.55%

Asset Allocation

Weighting Return Low Return High PBE % Rank
Stocks 		100.04% 87.34% 106.13% 2.52%
Cash 		20.06% 0.00% 33.01% 2.52%
Preferred Stocks 		0.00% 0.00% 7.86% 45.91%
Other 		0.00% -22.99% 23.24% 52.83%
Convertible Bonds 		0.00% 0.00% 0.37% 26.62%
Bonds 		0.00% 0.00% 12.39% 43.40%

Stock Sector Breakdown

Weighting Return Low Return High PBE % Rank
Healthcare 		100.00% 59.26% 100.00% 16.23%
Utilities 		0.00% 0.00% 0.00% 22.08%
Technology 		0.00% 0.00% 22.69% 29.22%
Real Estate 		0.00% 0.00% 5.89% 25.97%
Industrials 		0.00% 0.00% 7.02% 27.92%
Financial Services 		0.00% 0.00% 1.60% 45.45%
Energy 		0.00% 0.00% 0.00% 22.08%
Communication Services 		0.00% 0.00% 9.11% 25.32%
Consumer Defense 		0.00% 0.00% 25.73% 31.17%
Consumer Cyclical 		0.00% 0.00% 1.92% 27.92%
Basic Materials 		0.00% 0.00% 7.16% 51.95%

Stock Geographic Breakdown

Weighting Return Low Return High PBE % Rank
US 		100.04% 66.06% 104.41% 1.89%
Non US 		0.00% 0.00% 28.87% 69.18%

PBE - Expenses

Operational Fees

PBE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.58% 0.08% 4.48% 83.02%
Management Fee 0.50% 0.03% 1.25% 14.47%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

PBE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

PBE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

PBE Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 151.00% 0.00% 238.00% 94.81%

PBE - Distributions

Dividend Yield Analysis

PBE Category Low Category High PBE % Rank
Dividend Yield 0.05% 0.00% 6.24% 35.22%

Dividend Distribution Analysis

PBE Category Low Category High Category Mod
Dividend Distribution Frequency Quarterly Annual Quarterly Annual

Net Income Ratio Analysis

PBE Category Low Category High PBE % Rank
Net Income Ratio -0.30% -2.54% 1.85% 54.61%

Capital Gain Distribution Analysis

PBE Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Distributions History

View More +

PBE - Fund Manager Analysis

Managers

Peter Hubbard

Start Date

Tenure

Tenure Rank

Jun 01, 2007

15.01

15.0%

Peter Hubbard, Vice President and Director of Portfolio Management of the Invesco PowerShares Capital Management LLC. Mr. Hubbard has been a Portfolio Manager of the Adviser since June 2007 and has been associated with the Adviser since 2005. Prior to joining the Invesco PowerShares Capital Management LLC, Hubbard was a research analyst and trader for Ritchie Capital from September 2003 to May 2005.

Michael Jeanette

Start Date

Tenure

Tenure Rank

Aug 30, 2008

13.76

13.8%

Michael Jeanette, Senior Portfolio Manager of Invesco Capital Management LLC, has been associated with Invesco Capital Management LLC since 2008. Prior to joining Invesco Capital Management LLC, Mr. Jeanette was a trust advisor and GM of Chicago based Richard Lamb, LLC from 1998 to 2007.

Tony Seisser

Start Date

Tenure

Tenure Rank

Aug 29, 2014

7.76

7.8%

Tony Seisser is a Vice President and Portfolio Manager of Invesco PowerShares Capital Management LLC since December 2013. Prior to joining the Adviser, he was employed by Guggenheim Funds Distributors, Inc. where he was a trader from 2010 to 2013. Prior to that, Mr. Seisser was a compliance investigator at the Chicago Board of Options Exchange and Chicago Futures Exchange from 2008 to 2010.

Pratik Doshi

Start Date

Tenure

Tenure Rank

Aug 28, 2020

1.76

1.8%

Pratik Doshi is a Portfolio Manager of Invesco Capital Management. Mr. Doshi has been a Portfolio Manager of Invesco Capital Management since October 2019 and has been associated with Invesco Capital Management since 2018. Prior to joining Invesco Capital Management, Mr. Doshi was a business student in the MBA program at the University of Chicago from 2016 to 2018. From 2014 to 2016, he served as a Vice President at Bank of America, and from 2007 to 2014 he served as Assistant Vice President at Barclays Capital.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.